Atypical Hemolytic Uremic Syndrome Clinical Trials in Beijing
2 recruitingBeijing, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Phase 3
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals125 enrolled6 locationsNCT05795140